REVEAL GENOMICS, S.L.

Las guías reconocen la capacidad predictiva del HER2DX® y su papel en la toma de decisiones para la optimización del tratamiento. Le concede una clasificación II, B, la misma que poseen algunos de los tests genómicos ya utilizados de forma rutinaria por los oncólogos en cáncer de mama HER2-negativo.

🎉 Celebrating 4 amazing years today! This milestone is just the beginning, thanks to our visionary leadership, committed team, and everyone who trusts us. We are dedicated to transforming cancer care to benefit patients. 🚀 #breastcancer #HER2DX #DNADX #TNBCDX

🎉 Excited to share our latest review in Nature Reviews Clinical Oncology! 📖 We dive into the latest on dual #HER2 inhibition in #BreastCancer—exploring synergy, patient selection, and resistance. 🔬💥 Big steps forward in personalized treatment for patients with HER2+ breast cancer, and more to come! 💪🧬 👉 https://lnkd.in/d5fAwT6u #HER2DX #PrecisionMedicine Dana-Farber Cancer Institute Hospital Clínic de Barcelona Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) Universitat de Barcelona

More great news coming your way! 🎉 We’re thrilled to introduce TNBCDX® — the first genomic test designed specifically for early-stage Triple Negative Breast Cancer. Across two independent validation studies with 418 patients, the TNBCDX® scores showed a strong association with pathological complete response (pCR), distant disease-free survival (DDFS), and overall survival (OS). Check out the press release https://ow.ly/B2Ar50TlRJh or join us at #ESMO2024 for the session at 10:50 a.m. on September 14th, 2024, at the Barcelona Auditorium, led by Miguel Martín Don’t miss it!

🔴 This week is packed with exciting news! #HER2DX has delivered outstanding results in the CLEOPATRA trial. The levels of ERBB2 mRNA measured by #HER2DX have shown a significant association with PFS and OS. 🌟 More good news soon! ⭐️ Press Release here 👉🏻 https://ow.ly/i9Cl50Tk1a9

⭐️⭐️⭐️⭐️⭐️We are proud to have one of the best among us. Our CSO & co-founder Aleix Prat MD, PhD has been recognized by FORBES España as one of the 100 best doctors in Spain. (Article in Spanish.) https://ow.ly/51W350T9Jh2 #precisiononcology #HER2DX

Now available: the online publication of PHERGAIN, a collaboration with MEDSIR exploring the predictive capability of #HER2DX following (neo)adjuvant trastuzumab-pertuzumab-based therapy in HER2+ #breastcancer at AACR Journals #precisiononcology Read the full text here: https://ow.ly/rk5C50SM5bR

🎉 Excited to share that yesterday we submitted our article for publication on the development and validation of TNBC-DX, a new genomic profiling tool for the treatment of early-stage triple-negative breast cancer (TNBC) 📃 The validation of the test was possible thanks to our partnership with Dr. Miguel Martin, Dr. Oleg Gluz, and Dr. Nadia Harbeck 👨⚕️ 👩⚕️ 👨⚕️ The data will be presented at #ESMO24 in Barcelona! 🏢 With TNBC-DX, REVEAL GENOMICS, S.L. will have a 2nd product in early-stage breast cancer, ensuring genomic profiling across TNBC and HER2+ Both tests share similarities as they unlock the potential of the patient´s immune system and their tumor characteristics #COI

Excited to share our latest publication in Nature Communications (Nature Portfolio) on Patritumab Deruxtecan (HER3-DXd) in HER2-negative breast cancer! 🌟📚 Findings from the SOLTI-1805 TOT-HER3 trial show promising efficacy and identify key genetic markers for early response. Expertly led by Fara Brasó Maristany 👩🔬✨ Dive into the details here: https://shorturl.at/v67B9 📖🔍 Mafalda Oliveira Juan M. Ferrero-Cafiero Hospital Clínic de Barcelona Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) Universitat de Barcelona Vall d'Hebron Institute of Oncology (VHIO) SOLTI REVEAL GENOMICS, S.L. Daiichi Sankyo Europe GmbH

Guillermo Villacampa Javierre on #HER2DX at ESMO - European Society for Medical Oncology is a good start to the week! #ESMOBreast24 #breastcancer #precisiononcology